# Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines

> **NCT03753074** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Young-Suk Lim** · enrollment: 780 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** Tenofovir Alafenamide

## Key facts

- **NCT ID:** NCT03753074
- **Lead sponsor:** Young-Suk Lim
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-18
- **Primary completion:** 2031-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 780 (ESTIMATED)
- **Last updated:** 2024-12-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03753074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03753074, "Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03753074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*